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Running title: Mitochondria possess alloantigenicity. 
 
Summary 
The generation of pluripotent stem cells by somatic cell nucleus transfer (SCNT) has recently 
been achieved in human cells and sparked new interest in this technology. The authors 
reporting this methodical breakthrough speculated that SCNT would allow the creation of 
patient-matched embryonic stem cells, even in patients with hereditary mitochondrial diseases. 
However, herein we show that mismatched mitochondria in nuclear transfer-derived embryonic 
stem cells (NT-ESC) possess alloantigenicity and are subject to immune rejection. In a murine 
transplantation setup, we demonstrate that allogeneic mitochondria in NT-ESCs, which are 
nucleus-identical to the recipient, may trigger an adaptive alloimmune response that impairs the 
survival of NT-ESC grafts. The immune response is adaptive, directed against mitochondrial 
content, and amenable for tolerance induction. Mitochondrial alloantigenicity should therefore be 
considered when developing therapeutic SCNT-based strategies. 
 
Highlights 
 Mismatched mitochondria in nuclear transfer-derived embryonic stem cells (NT-ESC) 
possess alloantigenicity and are subject to immune rejection. 
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 The alloimmune response against mitochondria mismatched NT-ESCs is weaker than 
that against major histocompatibility complex (MHC)-mismatched cell grafts. 
 The immune response is adaptive, directed against mitochondrial content, and 
amenable for tolerance induction. 
 
 
eTOC Blurb 
Mismatched mitochondria in SCNT-derived ESC grafts trigger immune rejection despite 
matching for the entire nuclear genome with the murine recipient. 
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In somatic cell nucleus transfer (SCNT), the nucleus of a somatic cell is transplanted into an 
enucleated oocyte (Noggle et al., 2011). It has been envisioned that by this means, autologous 
pluripotent stem cells can be generated for specific patient-matched therapies. Embryonic stem 
cells by nuclear transfer (NT-ESCs) were first successfully generated from mice (Munsie et al., 
2000) and primates (Byrne et al., 2007). After substantial optimization of the SCNT technique, 
the derivation of NT-ESCs from human fetal fibroblasts (Tachibana et al., 2013), and most 
recently, also from adult somatic cells (Chung et al., 2014; Yamada et al., 2014) was reported. 
These latter studies suggest that age-associated changes in the nucleus donor cell are not 
necessarily an impediment to generating human NT-ESCs (Chung et al., 2014). Furthermore, 
the differentiation of insulin-producing beta cells derived from NT-ESCs generated from a long-
standing diabetic patient proved that specialized cell types that were lost in diseased patients 
could be re-established (Yamada et al., 2014). Because NT-ESCs acquire healthy mitochondria 
from the selected oocyte donor, inherited or acquired mtDNA diseases are most amenable for 
correction using the SCNT technology (Tachibana et al., 2013). The recent advancements in 
SCNT methodology have increased expectations for this approach to lead to human-assisted 
reproductive technologies (Cibelli, 2014). 
A so far underappreciated obstacle for clinical application of SCNT-derived cell therapy may be 
the immunogenicity of mismatched mitochondria in NT-ESCs. After transplantation of NT-ESC-
derived cells or tissue back into the nucleus donor, mismatched mtDNA-coded proteins may 
induce alloimmunity. We here show that allogeneic mitochondria in murine NT-ESCs may 
trigger an adaptive immune response that impairs the survival of NT-ESC grafts. 
To assess mitochondria-specific alloantigenicity, transplantation studies with SCNT-derived 
murine NT-ESCs were conducted across defined immunological barriers. SCNT was performed 
as described earlier (Kirak et al., 2010) using enucleated BDF1 (B6D2F1/J) oocytes (C57BL/6J 
× DBA/2NCrl)F1 and isolated BALB/c (BALB/cAnNCrl; major histocompatibility complex (MHC) 
H2d) fibroblast nuclei (Figure 1A). Both oocytes and NT-ESCs demonstrated high mitochondrial 
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abundance (Figure S1A). The high repetition of mtDNA copies and high amount of 
mitochondrial proteins contributes to their relevance as possible immunogenic antigens. 
Culture-expanded NT-ESCs expressed markers related to pluripotency (Figure S1B). NT-ESCs 
grew tumors in immunodeficient NOD SCID mice (NOD.CB17-Prkdcscid/J). These tumors 
contained tissues of endodermal, ectodermal, and mesodermal origin (Figures S1C-D), thus 
meeting the criteria for teratomas. The generated NT-ESCs thus contain maternally-inherited 
C57BL/6J (B6) mitochondria and BALB/c nuclei of the H2d haplotype. Suspensions of 106 NT-
ESCs were intramuscularly injected into the thighs of recipient mice. BALB/c recipients are 
matched for the entire nuclear genome, but are mitochondria-mismatched. mtDNA sequence 
analysis comparing B6 mitochondria of the NT-ESCs with BALB/c mitochondria revealed 2 non-
synonymous nucleotide substitutions within the mt-Co3 and mt-Cytb genes, which resulted in 
amino acid substitutions in the associated proteins (Figure S2A). These two non-synonymous 
single nucleotide polymorphisms (SNPs) were therefore the only differences in the entire 
cellular DNA between donor cells and recipient. According to dbSNP (Sherry et al., 2001), both 
variants are common in mouse. The affected loci are conserved among vertebrates (Figure 
S2B) and for one of the two observed variants a human counterpart is described in dbSNP. 
BDF1 (H2b/d) recipients share the H2d alleles with the NT-ESCs, are mitochondria-matched, but 
minor histocompatibility antigen (MiHA)-mismatched (Figure 1A). B6 recipients possess the H2b 
haplotype and are therefore MHC-mismatched, but mitochondria-matched to the NT-ESCs. The 
severely immunodeficient NOD SCID strain was used as negative control, because it cannot 
mount any antigen-specific cellular immune response. The CBA (CBA/J; H2k) strain is both 
MHC and mitochondria mismatched to the NT-ESCs. mtDNA sequencing revealed identical 
mtDNA genomes for CBA and BALB/c, (not shown) as was previously reported in the context of 
mouse mtDNA phylogeny (Goios et al., 2007). Therefore, besides the MHC differences, NT-
ESC transplantations into BALB/c and CBA cross the same mitochondrial mismatch. 
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Previous studies on the immunogenicity of murine mitochondrial peptides were mostly restricted 
to cytotoxic T lymphocytes (CTLs) and MHC class Ia and Ib presentation (Dabhi and Lindahl, 
1995). We herein used assays that quantify activation of T helper cells (Th), because this entity 
plays a central role in activating CTLs and B cells, thus orchestrating graft rejection. Five-day 
ELISPOT assays for Th1-specific γ-interferon (IFNγ) showed a substantial immune activation in 
the MHC-mismatched B6 recipients, which was significantly stronger than those in 
mitochondria-mismatched BALB/c or MiHA-mismatched BDF1 (Figure 1B). The MHC- and 
mitochondria-mismatched CBA strain demonstrated the highest spot frequencies of all strains, 
which were approximately additive of the frequencies of the isolated MHC-mismatched B6 and 
the isolated mitochondria-mismatched BALB/c. The immunodeficient NOD SCID recipients 
showed immunological Th1 anergy. The Th2 response, although generally generating lower IL-4 
spot frequencies, showed a similar relation between the recipient strains (Figure 1C). There was 
also a surge in NT-ESC-specific IgM antibodies 5 days after immunization in B6 recipients, 
which was significantly stronger than those in BALB/c or BDF1 (Figure 1D). There were no NT-
ESC-specific IgM antibodies in NOD SCID. 
In an additional experiment, we could exclude that there were general differences among 
BALB/c, BDF1, and B6 in the degree of immune responsiveness (Figure S2C). Splenocytes of 
these three strains were unspecifically stimulated and ELISPOT assays demonstrated similar 
Th1 and Th2 activation. This result permits us to attribute the above ELISPOT results to the 
mismatched proteins. 
To exclude methodological bias by the SCNT technique itself, isogeneic BALB/c ESCs 
(isoESCs) were generated using SCNT with BALB/c donors for both oocytes and nuclei (Figure 
1E). Transplantation experiments were performed with fully nuclear DNA- and mtDNA-matched, 
isogeneic BALB/c recipients, MiHA- and mitochondria-mismatched BDF1, and MHC- and 
mitochondria-mismatched B6. There was negligible Th1 and Th2 activation in isogeneic BALB/c 
recipients (Figure 1F and G). Between mitochondria-mismatched recipients, an additional MHC 
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mismatch (B6) generated a significantly stronger Th1 activation than an additional MiHA 
mismatch (BDF1, Figure 1F). Together, these results demonstrate that an isolated mitochondria 
mismatch is sufficient to initiate marked Th activation and NT-ESC-directed antibody production. 
These immune responses are not caused by the SCNT technology itself. Second, an MHC 
mismatch causes a significantly stronger immune activation than a MiHA mismatch, both in the 
setting of additional mitochondrial match or mismatch. And third, the Th1 activation is additive 
for an MHC- and a mitochondria-mismatch. 
Based on the results by Ishikawa (Ishikawa et al., 2010), which assumed that the innate 
immunity was responsible for rejection of mitochondria-mismatched cell grafts, the T cell-
deficient nude mouse model was used to study the NK cell response. BALB/c nude (BALB/c 
nu/nu, CAnN.Cg-Foxn1<nu>/Crl; H2d) were used as recipients for either mitochondria-
mismatched NT-ESCs or fully isogeneic isoESCs (H2d, Figure 1H). Our results show that there 
was no increase in NK cell-driven IFNγ ELISPOT frequency in response to NT-ESCs compared 
to isoESCs (Figure 1I). Also, the survival of cell grafts was similar for NT-ESCs and isoESCs 
and all animals formed teratomas, thus excluding relevant innate rejection processes (Figure 
1J-K). Importantly, the transplantation experiment by Ishikawa was specifically designed to be 
mismatched for the maternally transmitted mitochondrial antigen (Mta) previously described by 
Fischer Lindahl (Fischer Lindahl et al., 1980). Our transplant setting avoids this incompatibility 
and, as a consequence, we did not observe relevant innate immunity-driven rejection. 
Survival of NT-ESC grafts and teratoma development were assessed in the transplantation 
settings of Figure 1A. As expected, all NT-ESC transplants survived and formed teratomas in 
NOD SCID recipients (Figure 2A), whereas all grafts were rejected in fully mismatched CBAs 
(Figure 2B). The rather mild Th1 activation in MiHA-mismatched BDF1 still allowed for 90% 
teratoma development of rapidly-proliferating NT-ESC grafts (Figure 2C), whereas there was 
only 20% teratoma growth in MHC-mismatched B6 (Figure 2D). In mitochondria-mismatched 
BALB/c, teratomas developed in 60% of the recipients, but the tumor growth was markedly 
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slowed (Figure 2E). Half of the tumors did not develop until day 50 to 90. Interestingly, there 
was a strong correlation between graft survival and Th1 activation in individual BALB/c animals 
(Figure 2F). Only BALB/c recipients with very low spot frequencies developed teratomas, 
whereas animals with at least moderate Th1 activation rejected their grafts. This further 
supports the notion of a T cell-mediated rejection process of mitochondria-mismatched grafts. 
To confirm a mitochondrial location of the immunogenic peptides, mitochondria of NT-ESCs 
were separated from the remainder of the cell (cytosol) and splenocytes of NT-ESC-immunized 
BALB/c were re-stimulated in vitro with either mismatched mitochondria or isogeneic cytosol 
(Figure 2G). Only the mismatched mitochondria caused an IFNγ response, whereas the spot 
frequencies with the isogeneic cytosol fractions were low, similar to those of un-stimulated 
responder splenocytes (Figure 2H). Of note, the ELISPOT frequencies of the separated cell 
compartments were markedly lower than those involving whole cells. Although their precise 
presentation mechanism remains elusive, the detection of mitochondrial peptides in the context 
of MHC (Dabhi and Lindahl, 1995; Duvvuri et al., 2014) suggests they enter conventional MHC 
antigen presentation pathways. The dependence on indirect antigen presentation in this assay 
may explain this observation. In accordance with the ELISPOT results, in a delayed-type 
hypersensitivity test, only mismatched mitochondria generated paw swelling, whereas isogeneic 
cytosol did not (Figure 2I). The location of the antigens for BALB/c immune activation against 
NT-ESCs was thus restricted to the mitochondrial fraction. 
We next tested whether acquired immunological tolerance against allogeneic mitochondria can 
be induced. In accordance with the Medawar experiments (Billingham et al., 1953), neonatal 
BALB/c mice were immunized with mitomycin-inhibited NT-ESCs (Figure 2J). In adulthood, 
these animals were re-injected with NT-ESCs (BALB/cre-inject). In contrast to adult BALB/c 
recipients that received their first NT-ESC grafts, BALB/cre-inject showed no IFNγ response in 
ELISPOT assays and all animals developed teratomas (Figure 2K-L). This experiment not only 
shows that tolerance against allogeneic mitochondria can reliably be induced, it is also further 
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proof for the relevance of the adaptive immune system in rejecting mitochondria-mismatched 
grafts. 
There have been few publications on the transplantation of mitochondria-mismatched cells or 
tissues with conflicting results. Although prolonged hematopoietic chimerism (Lanza et al., 
2005) and acceptance of cardiac and renal cell transplants (Lanza et al., 2002) in cows 
receiving SCNT-derived mitochondria-mismatched cells was reported, this may not guarantee 
universal success. Pigs rejected kidney grafts from SCNT-derived mitochondria-mismatched 
clones (Kwak et al., 2013). In mice and rats, it was shown that a single non-synonymous 
nucleotide substitution in the mitochondrial ND1 gene or the ATPase 6 gene, respectively, 
generated an aberrant peptide and resulted in the loss of histocompatibility (Bhuyan et al., 1997; 
Davies et al., 1991; Loveland et al., 1990). Neopeptides from human mtDNA harboring large-
scale frameshift deletions were recently reported to bind to MHC molecules and can be 
recognized by T cells from other individuals (Duvvuri et al., 2014). Interestingly, their results 
further suggest that some neopeptides could bind promiscuously to both MHC class I and class 
II alleles, activate CD4 as well as CD8 T cells, and be recognized by CD8 memory T cells. 
Aberrant mitochondrial peptides may even provoke MHC overexpression and thus amplify their 
immunogenicity. In both mice and humans, increased MHC class I expression in cells harboring 
mtDNA deletions was shown (Gu et al., 2003). Mitochondrial peptides can thus serve as 
immunogens (Morse et al., 1996) and the recipient immune response may depend on the 
alloantigenicity of the aberrant mitochondrial protein. Although thought to be beneficial for 
immune surveillance and clearance of cells with mitochondrial mutations (Duvvuri et al., 2014; 
Gu et al., 2003), this immune feature is potentially hazardous in the context of SCNT-derived 
cell transplantation. 
Artificial reprograming using viral or non-viral plasmid-based approaches seems to alter the 
expression of a multitude of genes in induced pluripotent stem cells (iPSCs) that are 
differentially expressed in ESCs (de Almeida et al., 2014; Zhao et al., 2011). Specific factors 
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being suppressed (de Almeida et al., 2014) or overexpressed (Zhao et al., 2011) in the 
pluripotent state have been suggested to contribute to the antigenicity of iPSCs. With 
differentiation, the antigenicity was reported to vanish as transcriptome profile and surface 
antigen expression converged with those of corresponding somatic cells (de Almeida et al., 
2014). Terminally differentiated cells derived from iPSCs are now believed to possess no or 
negligible immunogenicity (Araki et al., 2013). The described immunogenicity is therefore 
differentiation-dependent and not due to antigenic somatic coding mutations, which have 
recently been reported to occur during reprogramming (Gore et al., 2011). When compared to 
autologous iPSCs that are fully matched for both nuclear and mitochondrial DNA, NT-ESCs with 
mtDNA differences to the nucleus donor possess additional allogeneic peptides that may 
potentially be antigenic. These antigenic proteins in mitochondria-mismatched NT-ESCs are 
maintained with differentiation and the mtDNA copies, if anything, are increased in energy-
consuming differentiated cells like cardiomyocytes. However, it remains to be determined if the 
results presented herein are transferrable to differentiated cells and tissues from NT-ESCs.  
The level of heterogeneity in human mitochondria is considerably higher than that in laboratory 
mice (Goios et al., 2007); dbSNP lists 2066 active human mitochondrial RefSNPs. At least 64 
thereof are common (global minor allele frequency 1% or higher) and non-synonymously 
coding. MT-CYTB is affected by 26 such variants and MT-CO3 by two, including the human 
counterpart of the murine variant we observed. A recent study hints at the level of heterogeneity 
in human mitochondrial genomes (Ridge et al., 2014). Within a dataset of 1007 full 
mitochondrial genomes, 899 single nucleotide variants, 26 insertions, and 20 deletions were 
identified. Compared to the human reference sequence, each individual carried on average 25.3 
variants. Single individuals marked the extremes with 2 and 52 variants, respectively. 
In the field of xenotransplantation, the immunity against the αGal-antigen was long considered 
to be the one obstacle that needed to be overcome to clear the path for subsequent clinical 
application. However, when αGal was knocked out, xeno-immune responses were still evident 
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and new immune targets surfaced that previously were overshadowed by the strong αGal 
response (Miyata and Platt, 2003). Similarly, when nuclear DNA is matched in SCNT-derived 
cells, antigenic competition (Johnson et al., 1981) may allow mitochondrial antigens to emerge 
as immunogens. The immunogenicity of mitochondria should thus not be neglected when 
advancing the SCNT technology. 
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Figure Legends 
Figure 1: NT-ESCs possess mitochondria-related antigenicity.  
(A) NT-ESCs were generated using enucleated BDF1 oocytes and isolated BALB/c fibroblast 
nuclei. NT-ESCs were transplanted into mitochondria-MM BALB/c, MiHA-MM BDF1, MHC-MM 
B6, immunodeficient NOD SCID, or combined MHC- and mitochondria-MM CBA. See also 
Figure S1. 
(B) Recipient-specific Th1 ELISPOT results against NT-ESCs showed significantly lower IFNγ 
spot frequencies for BALB/c (n=18) and BDF1 recipients (n=17) compared to B6 (n=24). 
Overall, the CBA IFNγ response (n=15) was the strongest and the NOD SCID response (n=6) 
negligible. 
(C) IL-4 (Th2) ELISPOT responses revealed similar relations among groups (BALB/c n=12, 
BDF1 n=17, B6 n=24, NOD SCID n=8, CBA n=10) as described in (B) for Th1 response. 
(D) The NT-ESC-specific IgM antibody production after 5 days was significantly stronger in B6 
(n=22) than in BALB/c (n=31) or BDF1 (n=15). No IgM antibodies against NT-ESCs were 
detected in NOD SCID (n=6). 
(E) Isogeneic SCNT-derived BALB/c ESCs (isoESCs) were generated from BALB/c oocytes and 
nuclei. isoESCs were transplanted either into isogeneic BALB/c or recipients with combined 
mitochondria- and MiHA-MM (BDF1) or mitochondria- and MHC-MM (B6). 
(F) The IFNγ ELISPOT responses against isoESC grafts were negligible in BALB/c (n=5) and 
significantly stronger in BDF1 (n=22) or B6 (n=6). Th1 activation in MHC-MM B6 was 
significantly stronger than in MiHA-MM BDF1. 
(G) The isoESC-specific IL-4 ELISPOT responses were significantly stronger in BDF1 (n=23) 
and B6 (n=10) than in BALB/c (n=5). 
(H) BALB/c nude mice received NT-ESC (mitochondria-MM) or isoESC grafts. Because of the T 
cell deficiency, the nude model assesses NK cell responses. 
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(I) The IFNγ NK cell response against NT-ESCs (n=9) was similarly low as that against isoESCs 
(n=8). 
(J-K) Teratoma growth diagrams for NT-ESCs (J, n=5) and isoESCs (K, n=5) in BALB/c nude 
mice are shown. The overall teratoma development is depicted in separate adjacent graphs. 
On each box in ELISPOT blots, the central mark is the median, the edges of the box are the 
25th and 75th percentiles, and the whiskers extend to the most extreme data points. 
MM=mismatch, * p<0.05. 
 
Figure 2: The rejection of mitochondria-MM NT-ESCs is adaptive, directed against 
mitochondrial content, and amenable for tolerance induction. 
(A-E) Teratoma growth diagrams for NT-ESC grafts in immunodeficient NOD SCID (A, n=5), 
combined MHC- and mitochondria-MM CBA (B, n=5), MiHA-MM BDF1 (C, n=10), MHC-MM B6 
(D, n=10), and mitochondria-MM BALB/c recipients (E, n=10). The overall teratoma 
development is depicted in separate adjacent graphs. See also Figure S2. 
(F) Within the BALB/c recipient group, the IFNγ ELISPOT frequencies of animals that did not 
(no teratoma, n=20) or did show teratoma growth (teratoma, n=8) were compared. 
(G) BALB/c received mitochondria-MM NT-ESC grafts. Subsequent ELISPOT assays did not 
use NT-ESCs, but isolated mitochondria or the remainder of the cells (referred to as cytosol) for 
stimulation. 
(H) IFNγ ELISPOT analyses show some BALB/c response against isolated NT-ESC 
mitochondria (NT-ESCmito, n=8), whereas no reactivity against the mitochondria-depleted NT-
ESC remnants (NT-ESCcytosol, n=4) was detectable. 
(I) There also was a paw swelling response in BALB/c recipients challenged with cutaneous 
injections of isolated NT-ESC mitochondria (n=9), but not in BALB/c challenged with the 
mitochondria-depleted NT-ESC remnants (n=5). 
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(J) One group of BALB/c mice received their first NT-ESC grafts at neonatal stage and was re-
injected during adulthood (BALB/cre-inject). The other group received NT-ESC grafts only after 
entering adulthood (BALB/c).  
(K) In ELISPOT assays, BALB/cre-inject (n=14) showed a significantly lower IFNγ response than 
BALB/c (n=7). 
(L) The overall teratoma development of NT-ESC grafts in BALB/cre-inject (n=27) and BALB/c 
animals (n=7) is presented. 
On each box in ELISPOT blots, the central mark is the median, the edges of the box are the 
25th and 75th percentiles, and the whiskers extend to the most extreme data points. In each 
scatter blot, the central mark is the median. MM=mismatch, † p<0.01. 
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Figure S1: Characterization of SCNT-derived NT-ESCs and proof of pluripotency. 
(A) A murine oocyte (upper row) and an NT-ESC (lower row) were stained for nuclear (Hoechst) 
and mitochondrial content (Mitotracker). Confocal immunofluorescence shows the defined 
nucleus and the great abundance of mitochondria throughout the cells.  
(B) SCNT-derived NT-ESCs demonstrated pluripotency markers as they were positive for 
alkaline phosphatase (AP), and expressed SSEA-1, Sox2, and Oct4. 
(C) NT-ESCs were transplanted into immunodeficient NOD SCID mice and grew tumors within 
3-4 weeks. Recovered tumors stained positive for tissues of all three germ layers and were thus 
identified as teratomas. Endodermal (cytokeratin 8), mesodermal (brachyury), and ectodermal 
(GFAP) lineages were demonstrated by confocal immunofluorescence microscopy. 
(D) Hematoxylin-eosin staining of NT-ESC-derived teratomas revealed their composition of 
various types of tissues. Upper row (left to right): primitive neural tube differentiation (ectoderm), 
squamous epithelium (ectoderm), brain tissue (ectoderm), bronchial and clear cell bronchogenic 
epithelium and bone (endoderm and mesoderm). Lower row (left to right): hair follicles with 
sebaceous glands (ectoderm), intestine (endoderm), smooth muscle (mesoderm), striated 
muscle (mesoderm). 
  
  
 
Figure S2: Mitochondrial DNA (mtDNA) sequencing, level of conservation among vertebrates, 
and unspecific immune responsivenesses of different mouse strains.  
(A) The comparison of mtDNA sequences between isolated B6 mitochondria and BALB/c 
mitochondria revealed two non-synonymous nucleotide substitutions. 
(B) Multiple sequence alignments of mt-Co3 (upper part) and mt-Cytb (lower part). The level of 
conservation for each position is indicated by bars and background colors. The positions 
affected by variants observed in this study are highlighted. Alignments were calculated using 
Muscle (v3.8.31) (Edgar, 2004) with default parameters. For visualization, UGENE (v1.11.5) 
(Okonechnikov et al., 2012) was employed. 
(C) BALB/c (n=10), BDF1 (n=10 for IFNγ and n=5 for IL-4), and B6 (n=10) splenocytes were 
stimulated with PMA and ionomycin for 24h. The IFNγ and IL-4 ELISPOT frequencies were 
similar among the mouse strains. 
 
  
Experimental Procedures 
Generation and culture of NT-ESCs and isoESCs 
Somatic cell nuclear transfer (SCNT) 
Oocytes from superovulated BDF1 or BALB/c mice were metaphase-II arrested and enucleated. 
Nuclei from BALB/c were transferred into the enucleated oocytes to create NT-ESCs and 
isoESCs, respectively. 
Cell culture 
NT-ESCs and isoESCs were cultured on mitomycin-inhibited CF1 feeders using standard ES 
cell media (Gibco, Darmstadt, Germany) containing LIF (Millipore, Billerica, MA). Before in vivo 
cell injection and in vitro immunology experiments, NT-ESCs and isoESCs were cultured on 
gelatin (Millipore) without feeders using standard media containing LIF. Cell cultures were 
regularly screened for mycoplasma infections (Lonza, Cologne, Germany). 
 
Mice 
BALB/c (BALB/cAnNCrl, H2d), BDF1 (B6D2F1/J, H2b/d), C57BL/6 (C57BL/6J, B6, H2b), NOD 
SCID (NOD.CB17-Prkdcscid/J), CBA (CBA/J, H2k), and BALB/c nude (BALB/c NU/NU, CAnN.Cg-
Foxn1<nu>/Crl, H2d) (all 6-10 weeks of age) were used as recipients for NT-ESC or isoESC 
grafts. Mice were purchased from Charles River Laboratories (Sulzfeld, Germany) and received 
humane care in compliance with the Guide for the Principles of Laboratory Animals. Mouse 
studies were approved by the Hamburg “Amt für Gesundheit und Verbraucherschutz”. The 
numbers of mice per experimental group are presented with each figure. 
 
Immunostaining in vitro 
The mouse ESC/iPSC Characterization Kit (Applied StemCell, Sunnyvale, CA) was used to 
demonstrate the expression of the pluripotency markers alkaline phosphatase (AP), SSEA-1, 
Sox2, and Oct4. Staining was performed according to the manufacturer’s protocol. 
 
In vivo teratoma assay 
Teratoma formation was observed within 4 weeks after injecting 107 NT-ESCs intramuscularly 
into NOD SCID mice and teratomas were fixed with 4% paraformaldehyde and paraffin-
embedded for confocal immunofluorescence and histopatholgy.  
To demonstrate pluripotency using immunostainings, 5µm sections underwent heat-induced 
antigen retrieval with Dako antigen retrieval solution (Dako, Glostrup, Denmark) in a steamer 
followed by blocking with Image-iT® FX signal enhancer (Invitrogen, Carlsbad, CA). Sections 
were incubated with a primary antibody against brachyury (ab20680, Abcam, Cambridge, 
England). For detection, a goat anti-rabbit antibody labeled with Alexa Fluor 555 (Invitrogen) 
was used. Subsequently, sections were incubated with FITC- and Alexa Fluor 647-conjugated 
antibodies against cytokeratin 8 (SB37b, Abcam) and GFAP (GA5, Cell signaling, Cambridge, 
UK), respectively.  After nuclei staining with DAPI, images were obtained and analyzed using 
the Nikon Eclipse TiE microscope (Nikon, Tokyo, Japan) equipped with Perkin Elmer UltraVIEW 
VoX confocal imaging system (Perkin Elmer, Waltham, MA). Hematoxylin and eosin (H&E) 
stained slides were interpreted by an expert pathologist (J.V.) blinded to the study.  
 
Live cell mitochondrial staining 
Living cells were incubated in Mitotracker FM staining solution (0.1μM; Invitrogen) for 15 min at 
37°C. Cell nuclei were stained with Hoechst 33342 (0.3μM; Invitrogen). Immediately after 
staining, images were taken with a Nikon Eclipse TiE microscope equipped with Perkin Elmer 
UltraVIEW VoX confocal imaging system (Perkin Elmer). Cropped pictures of single cells are 
presented. 
 
mtDNA sequencing 
B6, BALB/c, and CBA mtDNA sequencing was performed as previously described (Trifunovic et 
al., 2004). Results were compared to known SNPs in the Database of Single Nucleotide 
Polymorphisms (dbSNP; National Center for Biotechnology Information, National Library of 
Medicine, Bethesda, MD). dbSNP build IDs: 141 (human) and 140 (mouse) are available from 
http://www.ncbi.nlm.nih.gov/SNP/. 
 
Cell transplantation 
Before transplantation, NT-ESCs and isoESCs were cultured off-feeder for 1 passage to avoid 
contamination with feeder cells. NT-ESCs and isoESCs were trypsinated and re-suspended in 
sterile saline for immunobiology experiments (106 cells per 80µl saline for ELISPOT, 107 cells 
per 80µl saline for DTH) and NT-ESC graft survival studies (106 cells per 80µl saline). Cell 
viability was approximately 95% as determined by trypan blue staining. Cell transplantation was 
performed by direct injection of cell suspensions into the right thigh muscle of recipient mice 
using a 27-gauge syringe.  
 
ELISPOT assays  
For uni-directional Enzyme-Linked ImmunoSpot (ELISPOT) assays, recipient splenocytes were 
isolated from fresh spleen 5 days after NT-ESC or isoESC injection and used as responder 
cells. NT-ESCs or isoESCs were mitomycin-inhibited and served as stimulator cells. 105 
stimulator cells were incubated with 5x105 recipient responder splenocytes for 24h and IFNγ 
and IL-4 spot frequencies were automatically enumerated using an ELISPOT plate reader. 
Duplicates or quadruplicates were performed in most assays. 
To measure the ELISPOT response to cell compartments (mitochondria or cytosol), 
mitochondria were isolated from 3x107 NT-ESCs and served as stimulators. The remainder of 
the cells comprised the cytosol fraction. Successful separation of mitochondria and 
mitochondria-depleted cytosol was confirmed by immunoblots. Mitochondrial complex IV and 
GAPDH were used to confirm mitochondrial and cytosol content, respectively, and to rule out 
cross-contamination. 
In accordance to the Medawar experiments, neonatal BALB/c mice were immunized with 105 
mitomycin-inhibited NT-ESCs. In adulthood, the animals were re-injected with 106 NT-ESCs  
(Balb/Cre-inject) and uni-directional ELISPOT assays were performed as describe above.  
Unspecifically stimulated BALB/c, BDF1, and B6 splenocytes served as ELISPOT controls. For 
these assays, 3x104 responder splenocytes were stimulated with PMA (phorbol 12-myristate 13-
acetate, Sigma, 1ng/ml) and ionomycin (Sigma, 500ng/ml) for 24 h. 
 
Delayed-type hypersensitivity response (DTH) 
DTH is a rapid T cell-dependent in vivo immune response to a foreign antigen, which the host 
immune system has experienced in the recent past. In the sensitization phase, 2x106 NT-ESCs 
were injected subcutaneously into the flank of BALB/c mice. Seven days after sensitization, 
heated mitochondria or cytosol fractions, obtained from 106 NT-ESCs, were intradermally 
injected into the footpad during the challenge phase and paw swelling was measured after 24h 
using a digimatic micrometer (Mitutoyo, Aurora, IL). Results are demonstrated as swelling 
response to the antigen challenge in comparison to the PBS-injected contralateral control 
footpad of the animals. 
 
NT-ESC-specific antibody assay using flow cytometry (FACS) 
NT-ESC-specific mouse antibodies were detected by FACS analysis as previously described 
(Deuse et al., 2008). Briefly, the serum of BALB/c, BDF1, and B6 mice 5 days after 
transplantation of NT-ESC grafts was incubated with NT-ESCs and the binding of antibodies 
was quantified. Only IgM antibodies were analyzed because of their known rapid surge within 5 
days after allogeneic stimulation. IgM antibodies were stained by incubation of the cells with a 
PE-conjugated goat antibody specific for the Fc portion of mouse IgM (BD Biosciences, Franklin 
Lakes, NJ). Cells were washed and then analyzed on a FACSCalibur system (BD Biosciences). 
Fluorescence data were expressed as mean fluorescence intensity (MFI). 
 
Survival of NT-ESC grafts 
Survival of NT-ESC grafts and teratoma development were assessed in vivo by injecting 107 
NT-ESCs or isoESCs in 80µl saline intramuscularly into the indicated recipients. Cell survival 
leading to teratoma formation was monitored every third day for 30 days using the digimatic 
caliper (Mitutoyo). Usually, teratoma formation occured within 30 days. However, animals not 
developing teratomas were followed for 150 days to exclude late teratoma development. The 
overall fractions of animals that developed teratomas are shown in separate adjacent graphs. 
 
Statistics 
In box blot graphs, the median is shown, the edges of the box are the 25th and 75th percentiles, 
and the whiskers extend to the most extreme data points. In scatter blots, the central mark is the 
median. Intergroup differences were appropriately assessed by either unpaired Student’s t test 
or one-way analysis of variance (ANOVA) with Bonferroni’s postHoc test. * p<0.05,  p<0.01. 
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